Depalmitoylation rewires FLT3-ITD signaling and exacerbates leukemia progression
Open Access
- 2 December 2021
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 138 (22) , 2244-2255
Abstract
Internal tandem duplication within FLT3 (FLT3-ITD) is one of the most frequent mutations in acute myeloid leukemia (AML) and correlates with a poor prognosis. Whereas the FLT3 receptor tyrosine kinase is activated at the plasma membrane to transduce PI3K/AKT and RAS/MAPK signaling, FLT3-ITD resides in the endoplasmic reticulum and triggers constitutive STAT5 phosphorylation. Mechanisms underlying this aberrant FLT3-ITD subcellular localization or its impact on leukemogenesis remain poorly established. In this study, we discovered that FLT3-ITD is S-palmitoylated by the palmitoyl acyltransferase ZDHHC6. Disruption of palmitoylation redirected FLT3-ITD to the plasma membrane and rewired its downstream signaling by activating AKT and extracellular signal-regulated kinase pathways in addition to STAT5. Consequently, abrogation of palmitoylation increased FLT3-ITD–mediated progression of leukemia in xenotransplant-recipient mouse models. We further demonstrate that FLT3 proteins were palmitoylated in primary human AML cells. ZDHHC6-mediated palmitoylation restrained FLT3-ITD surface expression, signaling, and colonogenic growth of primary FLT3-ITD+ AML. More important, pharmacological inhibition of FLT3-ITD depalmitoylation synergized with the US Food and Drug Administration–approved FLT3 kinase inhibitor gilteritinib in abrogating the growth of primary FLT3-ITD+ AML cells. These findings provide novel insights into lipid-dependent compartmentalization of FLT3-ITD signaling in AML and suggest targeting depalmitoylation as a new therapeutic strategy to treat FLT3-ITD+ leukemias.Keywords
This publication has 43 references indexed in Scilit:
- Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemiaBlood, 2012
- Palmitoylated calnexin is a key component of the ribosome–translocon complexThe EMBO Journal, 2012
- Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic NrasBlood, 2012
- Endoplasmic Reticulum Localization of DHHC Palmitoyltransferases Mediated by Lysine-based Sorting SignalsJournal of Biological Chemistry, 2011
- Palmitoylation of oncogenic NRAS is essential for leukemogenesisBlood, 2010
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Blood, 2009
- Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic CorrelatesCancer Cell, 2008
- Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse modelBlood, 2008
- Use of analogs and inhibitors to study the functional significance of protein palmitoylationMethods, 2006
- Tyrosine Phosphorylation Regulates Maturation of Receptor Tyrosine KinasesMolecular and Cellular Biology, 2005